Investment of the week: Jnana Therapeutics launches with a US$ 50 m Series A investment to target th
The Boston-based biotech Jnana Therapeutics just announced its launch with a US$ 50m Series A financing. Its focus will be to build the first discovery platform dedicated to targeting the solute carrier (SLC) family of transporters. The SLC transporters is a family of more than 300 membrane-bound proteins that facilitate the transport of a wide array of substrates across biological membranes. The SLC transporters have important roles in physiological processes, ranging from the cellular uptake of nutrients to the absorption of drugs and other xenobiotics. Several classes of marketed drugs target SLC transporters, such as neurotransmitter transporters for instance. In addition, human genetic